We are live on ! Find out more
PCRX icon

Pacira BioSciences
PCRX

276 hedge funds and large institutions have $3.04B invested in Pacira BioSciences in 2021 Q4 according to their latest regulatory filings, with 46 funds opening new positions, 105 increasing their positions, 82 reducing their positions, and 26 closing their positions.

New
Increased
Maintained
Reduced
Closed

77% more first-time investments, than exits

New positions opened: 46 | Existing positions closed: 26

33% more funds holding in top 10

Funds holding in top 10: 3 → 4 (+1)

28% more repeat investments, than reductions

Existing positions increased: 105 | Existing positions reduced: 82

11% more capital invested

Capital invested by funds: $2.75B → $3.04B (+$298M)

7% more funds holding

Funds holding: 259 → 276 (+17)

3.11% more ownership

Funds ownership: 110.52% → 113.63% (+3.1%)

67% less call options, than puts

Call options by funds: $1.67M | Put options by funds: $5.08M

Holders
276
Holders Change
+17
Holders Change %
+6.56%
% of All Funds
4.25%
Holding in Top 10
4
Holding in Top 10 Change
+1
Holding in Top 10 Change %
+33.33%
% of All Funds
0.06%
New
46
Increased
105
Reduced
82
Closed
26
Calls
$1.67M
Puts
$5.08M
Net Calls
-$3.42M
Net Calls Change
-$7.42M

Top Buyers

Rank Fund Capital Flow
1
PC
Paulson & Co
New York
+$24.6M
2
AC
Armistice Capital
New York
+$20.7M
3
Baillie Gifford & Co
Baillie Gifford & Co
United Kingdom
+$14.7M
4
Marshall Wace
Marshall Wace
United Kingdom
+$10.5M
5
HCM
Hodges Capital Management
Texas
+$9.26M

Top Sellers

Rank Fund Capital Flow
1
DM
Deerfield Management
New York
-$20.5M
2
Wells Fargo
Wells Fargo
California
-$18M
3
NPIC
Neumeier Poma Investment Counsel
California
-$16.2M
4
Goldman Sachs
Goldman Sachs
New York
-$14.3M
5
TA
Tamarack Advisers
California
-$7.44M
Name Holding Trade Value Shares
Change 		Change in
Stake
Lazard Asset Management
201
Lazard Asset Management
New York
$236K +$217K +3,934 New
AT
202
American Trust
Kentucky
$234K +$215K +3,893 New
SAM
203
Shell Asset Management
Netherlands
$228K +$662 +12 +0.3%
6M
204
6 Meridian
Kansas
$219K +$2.04K +37 +1%
OSAM
205
O'Shaughnessy Asset Management
Connecticut
$217K – – –
NCM
206
Next Capital Management
New York
$211K +$193K +3,500 New
AIP
207
Ameritas Investment Partners
Nebraska
$209K – – –
EWM
208
Evercore Wealth Management
New York
$205K +$188K +3,409 New
HighTower Advisors
209
HighTower Advisors
Illinois
$203K -$8.66K -157 -4%
Amundi
210
Amundi
France
$162K – – –
CAPTRUST Financial Advisors
211
CAPTRUST Financial Advisors
North Carolina
$153K +$5.46K +99 +4%
SOW
212
State of Wyoming
Wyoming
$139K +$11.5K +209 +10%
Nisa Investment Advisors
213
Nisa Investment Advisors
Missouri
$108K -$212K -3,846 -69%
PHK
214
Point72 Hong Kong
Hong Kong
$105K +$91.3K +1,656 +1,800%
KBC Group
215
KBC Group
Belgium
$97K – – –
VI
216
Vestcor Inc
New Brunswick, Canada
$72K -$7.5K -136 -10%
TFA
217
Toth Financial Advisory
Virginia
$68K – – –
EVM
218
Eaton Vance Management
Massachusetts
$65K +$31.4K +570 +113%
Simplex Trading
219
Simplex Trading
Illinois
$62K +$57.4K +1,041 New
Rockefeller Capital Management
220
Rockefeller Capital Management
New York
$58K -$10.4K -189 -16%
SPIA
221
Steward Partners Investment Advisory
New York
$56K -$9.65K -175 -16%
Nomura Holdings
222
Nomura Holdings
Japan
$51K -$229K -4,157 -83%
IA
223
IFP Advisors
Florida
$42K – – –
SWA
224
Sutton Wealth Advisors
Florida
$41K +$4.96K +90 +15%
HPC
225
HM Payson & Co
Maine
$39K -$33.1K -600 -48%
7 8
9
10 11

PCRX Hedge Fund Activity: Q4 2021 in Review

276 of the 6,498 institutional investors tracked by Wall St. Rank reported a position in Pacira BioSciences (PCRX) for Q4 2021, worth a combined $3.04B — up 11% from $2.75B a quarter earlier.

Buyers outnumbered sellers: 46 funds opened new PCRX positions and 26 closed out — a net gain of 20 holders — while 105 added to existing stakes and 82 trimmed.

The largest buyer was Paulson & Co, adding an estimated $24.6M. The largest seller was Deerfield Management, cutting an estimated $20.5M.

  • 276 institutional investors held Pacira BioSciences (PCRX) as of Q4 2021, up from 259 in Q3 2021.
  • Funds reported $3.04B of Pacira BioSciences stock for Q4 2021, up 11% quarter-over-quarter.
  • 46 funds opened new Pacira BioSciences positions in Q4 2021 and 26 closed out, a net change of +20 holders.
  • The largest Pacira BioSciences buyer in Q4 2021 was Paulson & Co, an estimated $24.6M added.
  • The largest Pacira BioSciences seller in Q4 2021 was Deerfield Management, an estimated $20.5M sold.

Based on aggregated 13F filings for Q4 2021.